CTIS2022-501507-27-00招募中1 期
TOPOLOGY : A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer - IC 2020-16
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Willing and able to comply with the protocol and provide written informed consent prior to study-specific screening procedures, Patients whose cancer has a CPS score =10 must have received prior pembrolizumab unless (i) contra-indicated (ii) CPS score or pembrolizumab not available at time of first line treatment start, Resolution of chemotherapy and radiation therapy related toxicities to NCI-CTCAE version 5.0 Grade 1 or lower severity, except for stable sensory neuropathy (= Grade 2), alopecia (any grade), presence of clinically managed chronic autoimmune AEs from prior immune therapy, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Adequate organ function (obtained within 14 days prior to treatment start) as evidenced by: i. Absolute neutrophil count (ANC) = 1.5 X 109/L; ii. Hemoglobin (Hgb) = 9 g/dL; iii. Platelet count = 100 X 109/L; iv. Bilirubin = 1.5 X upper limit of normal (ULN), except for patients with a documented history of Gilbert’s disease (= 2 X ULN); v. Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) = 2.5 X ULN (for patients with liver metastases = 5 X ULN); vi. Alkaline phosphatase (AP) = 3 X ULN (for patients with liver metastases, = 5 X ULN); vii. Serum creatinine = 1.5 mg/dL (133 µmol/L) or calculated creatinine clearance = 50 mL/min (using Cockcroft-Gault formula); viii. Women of childbearing potential (WCBP): negative serum pregnancy test, Patients covered by social security or health insurance in compliance with the national legislation relating to biomedical research, Age = 18 years, Females and males with cytologically or histologically confirmed breast carcinoma (either the primary or metastatic lesions), Locally advanced or metastatic disease that is not amenable to curative treatment, Triple negative breast cancer (both ER and PR <10%, HER2-negative or HER2-low), Measurable disease (per RECIST version 1.1), Prior therapy (administered in the neoadjuvant, adjuvant and/or metastatic setting) with an anthracycline, taxane and sacituzumab-govitecan (unless not medically appropriate or contraindicated for the patient), Received a minimum of two prior cytotoxic chemotherapy regimens for locally advanced or metastatic breast cancer, Patients with known gBRCA mutations must have received a PARP inhibitor in the metastatic setting.
排除标准
- •Patients who had a last dose of IV chemotherapy within 21 days, last dose of oral cytotoxic chemotherapy, radiotherapy, biological therapy, or investigational therapy within 14 days prior to treatment start, Severe/uncontrolled intercurrent illness within the previous 28 days prior to inclusion, Significant known cardiovascular impairment (NYHA CHF > grade 2, unstable angina, myocardial infarction within the previous 6 months prior to inclusion, or existing unstable cardiac arrhythmia), Any other significant medical, psychological, social or geographic conditions that in the opinion of the Investigator would impair study participation or cooperation, Patients deprived of their liberty or under guardianship, Patients who had any major surgery within 28 days prior to inclusion, Patients with chronic inflammatory bowel disease and/or bowel obstruction, Concomitant use of other agents for the treatment of cancer or any investigational agent(s), Brain metastases, unless local therapy was completed and use of corticosteroids for this indication discontinued for at least 3 weeks prior to inclusion. Signs or symptoms of brain metastases must be stable for at least 28 days prior to inclusion. No known progression of brain metastases (by imaging as assessed by RECIST) can have occurred. Patients with leptomeningeal disease or meningeal carcinomatosis are excluded, Women who are either pregnant, lactating, planning to get pregnant, Patients receiving pharmacotherapy for hepatitis B or C, tuberculosis, or HIV, Patients with known liver disease diagnosed with Child-Pugh A or higher cirrhosis, Prior stage III or IV malignancy (other than breast cancer)
研究者
相似试验
进行中（未招募）
不适用
A clinical study evaluating the efficacy of topical cromoglicate solution compared to placeboin the treatment of mastocytosisMedDRA version: 15.0Level: PTClassification code 10012812Term: Diffuse cutaneous mastocytosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 15.0Level: LLTClassification code 10056452Term: Indolent systemic mastocytosisSystem Organ Class: 10005329 - Blood and lymphatic system disordersmastocytosisEUCTR2011-006275-20-DEEO Pharma A/S
进行中（未招募）
1 期
A Phase II Study to determine the efficacy and safety of conventional dose oral Treosulfan in patients with advanced pre-treated Ewing’s Sarcoma - OTISEUCTR2005-003254-10-GBniversity College London25
进行中（未招募）
1 期
A phase II study investigating the efficacy and safety of Vvax001, a therapeutic cancer vaccine, in patients with premalignant cervical lesions.EUCTR2019-004050-29-NLniversity Medical Center Groningen18
招募中
2 期
A phase II study to determine the efficacy and safety of Vvax001, a therapeutic Semliki Forest Virus based cancer vaccine, in patients with HPV-16 induced grade 3 cervical intraepithelial neoplasia.NL-OMON55191niversitair Medisch Centrum Groningen18
已完成
2 期
The phase II study for evaluating the effectiveness and safety of allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia with FLT3/ITD mutation. -JALSG AML209-FLT3-SCT Study (AML209-FLT3-SCT)Acute myeloid leukemiaJPRN-UMIN000003433Japan adult leukemia study group60